Literature DB >> 15767511

Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.

Brian D Hoyt1, Paul J Massman, Christopher Schatschneider, Norma Cooke, Rachelle S Doody.   

Abstract

BACKGROUND: The apolipoprotein E epsilon4 (APOE epsilon4) allele is associated with an increased risk of developing Alzheimer disease (AD). However, findings regarding an association between the APOE epsilon4 allele and the rate of decline in AD have been mixed.
OBJECTIVE: To examine the relationship between the APOE epsilon4 allele and the rate of cognitive and functional decline in AD using individual growth curve analyses.
DESIGN: Longitudinal cohort study.
SETTING: Alzheimer Disease Research Center at Baylor College of Medicine. PATIENTS: A total of 189 patients meeting NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association) criteria for probable AD at baseline who underwent annual follow-up evaluations for at least 2 years. MAIN OUTCOME MEASURES: Individual growth curve parameters derived from baseline and follow-up performance on global and specific measures of cognitive and functional abilities.
RESULTS: Patients with 2 APOE epsilon4 alleles exhibited a slower rate of decline on measures of global cognitive functioning and functional abilities. No significant association was detected between the APOE epsilon4 allele and the rate of decline on measures of specific cognitive functions.
CONCLUSIONS: Although the APOE epsilon4 allele is associated with an increased risk of developing AD, it seems that having 2 APOE epsilon4 alleles is associated with a slower clinical course. These findings are consistent with hypotheses that the biological processes contributing to the onset of AD are different from those involved in determining its clinical course.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767511     DOI: 10.1001/archneur.62.3.454

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  31 in total

1.  Effects of general medical health on Alzheimer's progression: the Cache County Dementia Progression Study.

Authors:  Jeannie-Marie S Leoutsakos; Dingfen Han; Michelle M Mielke; Sarah N Forrester; JoAnn T Tschanz; Chris D Corcoran; Robert C Green; Maria C Norton; Kathleen A Welsh-Bohmer; Constantine G Lyketsos
Journal:  Int Psychogeriatr       Date:  2012-06-12       Impact factor: 3.878

2.  Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.

Authors:  Michael Gold; Claire Alderton; Marina Zvartau-Hind; Sally Egginton; Ann M Saunders; Michael Irizarry; Suzanne Craft; Gary Landreth; Ulla Linnamägi; Sharon Sawchak
Journal:  Dement Geriatr Cogn Disord       Date:  2010-08-21       Impact factor: 2.959

3.  Sex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline.

Authors:  May A Beydoun; Adel Boueiz; Marwan S Abougergi; Melissa H Kitner-Triolo; Hind A Beydoun; Susan M Resnick; Richard O'Brien; Alan B Zonderman
Journal:  Neurobiol Aging       Date:  2010-07-08       Impact factor: 4.673

4.  Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memory.

Authors:  S Barral; T Bird; A Goate; M R Farlow; R Diaz-Arrastia; D A Bennett; N Graff-Radford; B F Boeve; R A Sweet; Y Stern; R S Wilson; T Foroud; J Ott; R Mayeux
Journal:  Neurology       Date:  2012-04-25       Impact factor: 9.910

5.  Caregiver coping strategies predict cognitive and functional decline in dementia: the Cache County Dementia Progression Study.

Authors:  JoAnn T Tschanz; Kathleen Piercy; Chris D Corcoran; Elizabeth Fauth; Maria C Norton; Peter V Rabins; Brian T Tschanz; M Scott Deberard; Christine Snyder; Courtney Smith; Lester Lee; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2013-01-02       Impact factor: 4.105

6.  Hierarchical structure of the activities of daily living scale in dementia.

Authors:  F Delva; A Edjolo; K Pérès; C Berr; P Barberger-Gateau; J F Dartigues
Journal:  J Nutr Health Aging       Date:  2014-07       Impact factor: 4.075

7.  Functional integrity of thalamocortical circuits differentiates normal aging from mild cognitive impairment.

Authors:  Jose L Cantero; Mercedes Atienza; German Gomez-Herrero; Abel Cruz-Vadell; Eulogio Gil-Neciga; Rafael Rodriguez-Romero; David Garcia-Solis
Journal:  Hum Brain Mapp       Date:  2009-12       Impact factor: 5.038

8.  Survival in Alzheimer disease: a multiethnic, population-based study of incident cases.

Authors:  E P Helzner; N Scarmeas; S Cosentino; M X Tang; N Schupf; Y Stern
Journal:  Neurology       Date:  2008-11-04       Impact factor: 9.910

9.  Trajectories of cognitive decline in Alzheimer's disease.

Authors:  Patricia A Wilkosz; Howard J Seltman; Bernie Devlin; Elise A Weamer; Oscar L Lopez; Steven T DeKosky; Robert A Sweet
Journal:  Int Psychogeriatr       Date:  2009-09-28       Impact factor: 3.878

10.  Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition.

Authors:  Samantha C Burnham; Simon M Laws; Charley A Budgeon; Vincent Doré; Tenielle Porter; Pierrick Bourgeat; Rachel F Buckley; Kevin Murray; Kathryn A Ellis; Berwin A Turlach; Olivier Salvado; David Ames; Ralph N Martins; Dorene Rentz; Colin L Masters; Christopher C Rowe; Victor L Villemagne
Journal:  Neurobiol Aging       Date:  2020-06-10       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.